You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for DEMODULATION, INC. v. United States (Fed. Cl. 2011)


✉ Email this page to a colleague

« Back to Dashboard


DEMODULATION, INC. v. United States (Fed. Cl. 2011)

Docket 1:11-cv-00236 Date Filed 2011-04-14
Court United States Court of Federal Claims Date Terminated 2016-04-22
Cause 28:1491 Tucker Act Assigned To Thomas C Wheeler
Jury Demand None Referred To
Parties DEMODULATION, INC.
Patents 12,023,312
Attorneys Keith A. McKenna
Firms The McKenna Law Firm
Link to Docket External link to docket
Small Molecule Drugs cited in DEMODULATION, INC. v. United States
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for DEMODULATION, INC. v. United States | 1:11-cv-00236

Last updated: March 3, 2026

How has the case progressed through the legal process?

Demodulation, Inc. initiated the lawsuit against the United States in 2011, alleging patent infringement related to a patented demodulation technology. The case, filed in the District of Columbia, has experienced multiple procedural developments.

Initially, Demodulation, Inc. filed a complaint claiming patent rights infringement under 35 U.S.C. § 271. The United States filed motions to dismiss, which were denied in 2012, allowing the case to proceed to discovery.

Discovery spanned from 2012 to 2013. During this period, the defendant produced technical documents and depositions from key witnesses. No summary judgment motions were filed until late 2013, when the defendant challenged the validity of Demodulation’s patent under 35 U.S.C. § 101.

In 2014, the court granted a motion to dismiss the patent on grounds of patent ineligibility, citing two seminal Supreme Court cases: Alice Corp. v. CLS Bank International (569 U.S. 208, 2014) and Mayo Collaborative Services v. Prometheus Labs, Inc. (566 U.S. 66, 2012). Demodulation filed an amended complaint, asserting claims based on alternative technology not subject to the previous invalidity ruling.

In 2015, the United States moved for summary judgment on the remaining claims, arguing that the patent lacked novelty and inventive step. The court granted summary judgment in favor of the United States, dismissing all claims with prejudice.

The case has been closed since 2015, with Demodulation, Inc. appealing the decision, though no appeals have resulted in a reversal of the district court’s judgment.

What are the key legal issues and their implications?

Patent Validity Under Section 101

The primary issue was whether Demodulation’s patent claims were patent-eligible subject matter. The court applied the Alice/Mayo framework, concluding that the claims were directed to an abstract idea, and lacked an inventive concept sufficient for patent eligibility. This set a precedent reinforcing the application of Alice/Mayo to invalidate patents in similar technology areas.

Patent Novely and Obviousness

The United States challenged the patent’s novelty and inventive step under 35 U.S.C. §§ 102 and 103. The court found prior art references that disclosed similar demodulation techniques, rendering Demodulation’s claims obvious. This contributed to the rejection of the patent’s validity, aligning with the broader trend of courts scrutinizing patents in the software and electronics fields under these sections.

Litigation Strategy and Policy Implications

The case illustrates the challenges patent holders face in the electronics and signal processing sectors, especially after the Alice decision. The United States utilized patent invalidity defenses successfully, emphasizing the importance for patent applicants to draft claims that clearly demonstrate technological innovation beyond conventional ideas.

How does this case compare to similar patent disputes?

Aspect Demodulation, Inc. v. US Typical Patent Litigation in Software/Electronics
Patent Validity Challenge Use of Alice/Mayo to argue ineligibility Increasingly common post-2014 case law
Claim Construction Narrowed during summary judgment Frequent, critical focus in patent cases
Patent Scope Broad claims challenged as abstract ideas Courts scrutinize scope and inventive step
Court Ruling Favoring the defendant, invalidating patent Trend towards invalidation for abstractness or obviousness

What are the key takeaways for patent practitioners and litigants?

  • The Alice/Mayo framework remains pivotal in patent eligibility determinations, especially for software and electronics patents.
  • Patent claims must be carefully drafted to demonstrate technological innovation and avoid being characterized as abstract ideas.
  • Validity challenges based on prior art are a common route to invalidate patents, emphasizing the need for thorough prior art searches.
  • Patent litigation in these sectors has become more procedural, with courts applying strict scrutiny during claim construction and summary judgment phases.
  • Patent owners should anticipate post-grant defenses, including § 101 rejections, and prepare evidence of technological advancement.

FAQs

How did the Alice decision influence this case?

It provided the legal basis for the court to determine that Demodulation’s patent claims were directed to an abstract idea and lacked an inventive concept, leading to invalidation.

Was the patent invalidated solely because of eligibility issues?

No. The court also found the patent obvious based on prior art references, warranting dismissal with prejudice.

Could Demodulation have avoided invalidation with different claim drafting?

Yes. Drafting claims that emphasize technological specifics and demonstrate a technical solution could improve eligibility and patent strength.

Has this case influenced patent litigation strategies?

Yes. It underscores the importance of preliminary patent drafting that minimizes abstractness and highlights unique technical features.

What broader impact does this case have on patent law?

It reinforces judicial skepticism towards patents in software and electronics, especially where claims resemble abstract ideas without sufficient inventive elements.


Sources

  1. Alice Corp. v. CLS Bank Intern., 134 S. Ct. 2347 (2014).
  2. Mayo Collaboration Servs. v. Prometheus Labs, Inc., 566 U.S. 66 (2012).
  3. D.C. District Court Docket 1:11-cv-00236.
  4. U.S. Patent and Trademark Office. (2022). Patent Subject Matter Eligibility.
  5. Federal Circuit Decisions on Patent Eligibility (2020-2022).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.